home.aspx

 
. home.aspx home.aspx

ARCHIVED NEWS


    COSTS CURBING THE RISE OF ROBOTICS IN SPINAL SURGERY

    Nov 13, 2018

    The era of routine robotic-assisted spinal surgery is on the horizon. Despite the hype, however, there remains little market penetration, with affordability and the degree of value-added by such technology representing significant barriers to complete disruption of standard practice.
    In a rec...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=21172117

    THE GROWTH OF ROBOTIC PROCESS AUTOMATION IN LIFE SCIENCES AND PHARMA

    Nov 13, 2018

    Robotic process automation, sometimes called “intelligent automation”, simply put, refers to the use of software to perform routine or repetitive tasks. An overly simple example might be setting up an auto-response on your email account for when you’re not around to answer a sender...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=21182118

    ENTRESTO TOPS MAINSTAY ACE INHIBITOR IN HEART FAILURE TRIAL

    Nov 13, 2018

    Two years ago, Novartis launched a big trials programme for its heart failure drug Entresto in the hope of revving up disappointing initial sales, and one of those trials has just delivered positive results. The PIONEER-HF trial shows that Entresto (sacubitril/valsartan) is superior to the generic A...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=21192119

    GOOGLE HIRES GEISINGER CEO AS NEW HEALTH STRATEGY LEADER

    Nov 13, 2018

    Google has hired Geisinger Health CEO David Feinberg to provide strategic leadership as the tech giant moves into the health sector. In a statement, the Pennsylvania-based health firm Geisinger said Feinberg is leaving on 3 January, with chief medical officer Jaewon Ryu taking over as interim presid...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=21202120

    NANONEEDLE SKIN PATCH TO INJECT DRUGS INTO CELLS

    Nov 13, 2018

    Delivering drugs directly into skin cells using microscopic nanoneedles may allow for highly effective treatment of skin conditions without injuring the cells that are treated. Silicon nanoneedles have been developed in the past that can do such a trick, but they’re stiff and can be painful, i...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=21212121

    ROCHE’S TECENTRIQ GETS FAST REVIEW IN TRIPLE NEGATIVE BREAST CANCER

    Nov 13, 2018

    The FDA has granted a fast review for Roche/Genentech’s Tecentriq in combination with Celgene’s Abraxane for certain patients with tough-to-treat ‘triple negative’ breast cancer. The regulator has granted the immunotherapy Tecentriq (atezolizumab) and Abraxane (nab-paclitaxel...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=21222122

    TINY NEW PACEMAKER SMALL ENOUGH FOR INFANTS

    Nov 12, 2018

    Researchers at Children’s National Health System, working with engineers from Medtronic, have created a pacemaker appropriately tiny enough to implant into infants. Measuring only one cubic centimeter, about the size of a large pill, it allows the device to be implanted inside the child in a m...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=21112111

    DNA ORIGAMI NANOPARTICLES TO TREAT ACUTE KIDNEY INJURY

    Nov 12, 2018

    DNA origami is a technique for building differently shaped molecules out of the four standard nucleotide bases. Various forms can be constructed, such as tubes, pyramids, and cubes, and the shapes of these molecules can significantly affect their functionality. Now they’ve been shown to be use...


    READ MORE

    https://Pharmaceutical.report/news-article.aspx?ID=21122112

TRENDING NEWS


    AZ BEGINS LIVER CANCER IMMUNOTHERAPY TIE-UP WITH AVEO

    Dec 13, 2018

    AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer. AZ’s Imfinzi (durvalumab) immunotherapy has suffered a series of setbacks but the Anglo-Swedish pharma is still trying to find ways to enhance th...


    READ MORE

    https://pharmaphorum.com/news/az-begins-liver-cancer-immunotherapy-tie-up-with-aveo/2264

    NEUROCRINE SLUMPS AS TOURETTE’S DRUG FAILS CLINICAL TRIAL

    Dec 13, 2018

    Shares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed the mark. The phase IIb T-Force GOLD study of valbenazine showed that the VMAT2 inhibitor – already sold under the trade name Ingrezza for tardive dyskinesia (TD) &...


    READ MORE

    https://pharmaphorum.com/news/neurocrine-slumps-as-tourettes-drug-fails-clinical-trial/2265

    J&J’S TREMFYA OUTPERFORMS NOVARTIS’ COSENTYX IN PSORIASIS

    Dec 13, 2018

    A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease. Results from the late-stage study in moderate to severe plaque psoriasis showed that after 48 week...


    READ MORE

    https://pharmaphorum.com/news/jjs-tremfya-outperforms-novartis-cosentyx-in-psoriasis/2266

    NICE REJECTS ALNYLAM AND AKCEA’S AMYLOIDOSIS DRUGS

    Dec 13, 2018

    NICE has rejected two pioneering drugs for the rare inherited condition, hereditary transthyretin-related amyloidosis (hATTR) in the first draft guidance. The cost-effectiveness body had been using an assessment system for highly specialized technology when judging whether Alnylam’s Onpattro (...


    READ MORE

    https://pharmaphorum.com/news/nice-rejects-alnylam-and-akceas-amyloidosis-drugs/2267

    UAB RESEARCH MAY POINT A PATH TO MORE EFFECTIVE INFLUENZA VACCINES

    Dec 13, 2018

    Seasonal influenza vaccines are typically less than 50 percent effective, according to Centers for Disease Control and Prevention studies. Research at the University of Alabama at Birmingham, published this week in Nature Immunology, may point a path to more effective vaccines. Researchers led by Tr...


    READ MORE

    https://worldofmicrobes.com/uab-research-may-point-a-path-to-more-effective-influenza-vaccines/2268

    MATERIALISE AND CARESTREAM TO RELEASE BROWSER-DRIVEN PRE-OP AND 3D PRINTING SOFTWARE

    Dec 13, 2018

    Materialise, a company that 3D prints millions of unique medical parts every year, has partnered with Carestream Health to release a browser-driven pre-operative planning solution. The product will give orthopedic surgeons the ability to plan surgeries and order custom surgical guides and other 3D p...


    READ MORE

    https://www.medgadget.com/2018/12/materialise-and-carestream-to-release-browser-driven-pre-op-and-3d-printing-software.html2269

    MYLAN, BIOCON COPY INCHES CLOSER TO CHALLENGING SANOFI'S LONG-SUFFERING LANTUS

    Dec 13, 2018

    Sanofi’s Lantus is already facing off against generic competition from Eli Lilly and Boehringer’s Basaglar, but now Mylan is adding to the pressure by prevailing in a patent challenge at the U.S. Patent and Trademark Office. The PTO’s Patent Trial and Appeal Board invalidated two L...


    READ MORE

    https://www.fiercepharma.com/pharma/mylan-pressing-forward-lantus-biosim-prevails-patent-challenge-against-sanofi2270

    GARMIN TO DEVELOP WEARABLES FOR CLINICAL TRIALS WITH ACTIGRAPH

    Dec 13, 2018

    Tech-giant Garmin is stepping into the medical wearables space through a new collaboration with ActiGraph. The partnership will explore health and activity monitoring innovations combining Garmin wearables with ActiGraph‘s Centrepoint data analytics platform for academic research, clinical tri...


    READ MORE

    https://pharmaphorum.com/news/garmin-wearables-clinical-trials-actigraph/2271

    FDA HAILS 2018 AS BUMPER YEAR FOR DRUG DEVELOPMENT SUCCESSES

    Dec 13, 2018

    The FDA has hailed 2018 as a standout year for drug development and approvals, both in terms of the quantity and quality of activity. With the FDA approving 55 new molecular entities (NMEs) over the first 11 months of the year, 2018 has eased past 1996 to become the busiest year ever. Perhaps more i...


    READ MORE

    https://www.fiercebiotech.com/biotech/fda-hails-2018-as-bumper-year-for-drug-development-successes2272

    MERCK AND BRAZIL'S INSTITUTO BUTANTAN TEAM TO DEVELOP AT LEAST TWO DENGUE VACCINES

    Dec 13, 2018

    Merck & Company inked a research collaboration deal with Instituto Butantan, based in Sao Paulo, Brazil, to develop vaccines against dengue virus disease. Dengue fever infects as many as 400 million people annually, according to the U.S. Centers for Disease Control and Prevention (CDC). It is th...


    READ MORE

    https://www.biospace.com/article/merck-and-brazil-s-instituto-butantan-team-to-develop-at-least-2-different-dengue-vaccines/2273

    IMMUNOTHERAPY OPPORTUNITIES LIE IN GLIOMA MOLECULAR LANDSCAPE

    Dec 11, 2018

    Immunotherapy has proved effective in treating a number of cancers, but brain tumors have remained stubbornly resistant. Now, a new study suggests that a slow-growing brain tumor arising in patients affected by neurofibromatosis type 1 (NF1) may be vulnerable to immunotherapy, which gives the immune...


    READ MORE

    https://www.technologynetworks.com/biopharma/news/immunotherapy-opportunities-lie-in-glioma-molecular-landscape-313009?utm_campaign=Newsletter_TN_Brea2254

    SPRAYABLE GEL COULD HELP THE BODY FIGHT OFF CANCER AFTER SURGERY

    Dec 11, 2018

    Many people who are diagnosed with cancer will undergo some type of surgery to treat their disease — almost 95 percent of people with early-diagnosed breast cancer will require surgery and it’s often the first line of treatment for people with brain tumors, for example. But despite impro...


    READ MORE

    https://www.technologynetworks.com/cancer-research/news/sprayable-gel-could-help-the-body-fight-off-cancer-after-surgery-313005?utm_campaign=Newslette2255

    IDENTIFYING DIFFERENT TYPES OF CANCER CELLS USING AI

    Dec 11, 2018

    In cancer patients, there can be tremendous variation in the types of cancer cells from one patient to another, even within the same disease. Identification of the particular cell types present can be very useful when choosing the treatment that would be most effective, but the methods of doing this...


    READ MORE

    https://www.technologynetworks.com/cancer-research/news/identifying-different-types-of-cancer-cells-using-ai-313007?utm_campaign=Newsletter_TN_Breakin2256

    VANGUARD IEP PERIPHERAL BALLOON ANGIOPLASTY SYSTEM WITH EMBOLI FILTER CLEARED IN U.S.

    Dec 11, 2018

    Contego Medical, based in Raleigh, North Carolina, landed FDA clearance for its Vanguard IEP peripheral balloon angioplasty system. The product features the Congego’s proprietary Integrated Embolic Protection (IEP) technology that captures embolic debris breaking off from occlusions being trea...


    READ MORE

    https://www.medgadget.com/2018/12/vanguard-iep-peripheral-balloon-angioplasty-system-with-emboli-filter-cleared-in-u-s.html2257

    CERTAIN BRAIN TUMOURS COULD RESPOND TO IMMUNOTHERAPY

    Dec 11, 2018

    Some brain tumors may respond to immunotherapy after all, according to a new study. So far, brain tumours have been resistant to immunotherapy drugs because they are “cold” to the immune system and poor targets for this approach. But the research from Columbia University, published onlin...


    READ MORE

    https://pharmaphorum.com/news/certain-brain-tumours-could-respond-to-immunotherapy/2258

    JOHNSON & JOHNSON CHIEF FIGURES AMAZON COULD SHAKE UP PHARMA'S DISTRIBUTION, REBATES AND MORE

    Dec 11, 2018

    There’s been plenty of speculation about Amazon's intentions in pharmaceuticals, and now Johnson & Johnson’s CEO has weighed in on how the tech giant could affect drug markets by shaking up pharma distribution and reimbursement. Speaking with Fortune’s Susie Gharib, J&J...


    READ MORE

    https://www.fiercepharma.com/pharma/amazon-could-shake-up-distribution-reimbursement-for-pharma-j-j-ceo2259

SPOTLIGHT

Records and signatures in regulated environments can be either created on paper or electronically. In the past, the use of paper has been favored over electronic records and signatures. Advantages of electronic records compared to paper-based records are cost savings due to a reduced need for person

RESOURCES

Events